Moderna stock's recent surge might herald a shift in AI-focused dollars away from memory and data-center plays … and toward applications of generative AI tech. On Wednesday, Cambridge, Mass.-based Moderna (MRNA) soared 177% to hit a three-year high after announcing positive results in testing a vaccine for certain types of cancer. The tests showed a lengthening in relapses among patients…
Extract — continue reading at the source.
Related stories
Jim Cramer Says IBM Is A Hated Stock That Deserves Better
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
National Bank of Canada Q3 Earnings Call Highlights
Advanced Micro Devices (AMD) and Intel (INTC) Both Just Raised Billions for AI. Here’s How Their Strategies Differ
Price Prediction: Microsoft Will Hit $650 on This Date
Ferrari (RACE) vs. Tesla (TSLA): Ferrari’s $40M EV Record Shows How Luxury Scarcity Beats Tesla’s Mass-Market Volume